The ruling from Senior Judge Sarah Evans Barker also hinted that Congress needs to address the problems with the 340B Drug Pricing Program.
Feds buy another $1.29B worth of Lilly antibody treatment for COVID-19
The purchase will amount to 614,000 doses of two drugs, bamlanivimab and etesevimab, that make up the drug-cocktail infusion, Lilly said.Read More
Lilly misses earnings estimates but raises full-year outlook
Indianapolis-based Eli Lilly and Co. saw revenue in the third quarter increase 18 percent over the same period of 2020, to $6.77 billion.Read More
U.S. government buys $330M worth of COVID-19 antibody doses from Lilly
Eli Lilly’s therapy has been shown to be highly effective against the delta variant, which is now the dominant strain of the coronavirus in the United States.Read More
“A cut [in drug prices] like is being proposed would have about a 40% reduction in our U.S. revenues,” Lilly CEO David Ricks said in a television interview this week with Gerry Dick on Inside Indiana Business, a division of IBJ Media.
Two former job applicants, aged 55 and 49, filed a proposed class-action lawsuit in U.S. District Court in Indianapolis on Wednesday, accusing the Indianapolis-based drug maker of age discrimination.
Eli Lilly and Co. has produced at least two video commercials featuring Olympic swimmer Ryan Murphy promoting its migraine treatment, Emgality. But one of the ads contains a fleeting disclaimer: Murphy doesn’t take Emgality.
The mandate covers about 15,400 Lilly employees in numerous states and Puerto Rico, including about 11,000 in Indiana.
Eli Lilly and Co. turned in a profitable second quarter, but the results were shy of Wall Street analyst predictions. The drugmaker, however, saw revenue growth that topped Wall Street expectations.
Even as some drugmakers, including Indianapolis-based Eli Lilly and Co., are pushing to get experimental drugs approved, federal regulators are still dealing with a huge blowback over the controversial way they reviewed a new Alzheimer’s drug by rival Biogen.
The collaboration could be worth as much as $694 million and potential royalties to Verge Genomics if the two companies hit development milestones.
The role of the sticky substance in the brain has long divided researchers and is at the forefront again amid the FDA’s recent clearance of the first drug to treat the disease in almost two decades.
In her complaint, the lobbyist had claimed a top executive made sexist comments about her, mocked her physical appearance and subjected her and other women to a hostile work environment.
Eli Lilly and Co. shares jumped more than 9% Thursday morning after it received “breakthrough therapy” designation for donanemab from the U.S. Food and Drug Administration, putting the drug on a path that could expedite its development.
Mathilde Merlet oversees one of Eli Lilly and Co.’s fastest-growing products, a medicine called Taltz that treats a variety of dermatology and rheumatology disorders.
Shares of Biogen competitors soared after aducanumab became the first drug cleared by the U.S. Food and Drug Administration to slow the course of the mind-wasting disease that afflicts 6 million Americans.
For more than a century, Eli Lilly and Co. has pushed for innovation in the pharmaceutical industry. But six years ago, the drugmaker had to admit it was less than innovative in its own workforce.
Eli Lilly on Thursday said in a government filing that it has received a subpoena from the U.S. Justice Department for documents related to the factory and is cooperating with the investigation.
Shares of Eli Lilly and Co. dropped as much as 5% Tuesday morning after the Indianapolis-based drugmaker lowered guidance for full-year earnings.
The Indianapolis-based company is asking U.S. regulators to revoke their emergency authorization for the use of bamlanivimab alone, in favor of its combination with another drug.
Stephen Fry, Eli Lilly and Co.’s senior vice president for human resources and diversity, told a legislative committee Tuesday that the company believed the bill aimed at reducing voter fraud wasn’t needed.
Sonya Elling filed suit Friday in federal court against the drugmaker, alleging that Leigh Ann Pusey, senior vice president for corporate affairs and communications, precluded her from engaging with members of Congress because she was “not a cute, young thing.”